MedTrace Logo

Safety and Intraocular Pressure (IOP) Lowering Effect of AL-59412C

NCT01312454 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2013-10-25

No results posted yet for this study

Summary

The purpose of this study was to assess the safety and efficacy of AL-59412C injected intravitreally relative to Vehicle.

Conditions

Interventions

DRUG

AL-59412C injectable solution

Concentration 1 and Concentration 2

DRUG

Travoprost injectable solution

DRUG

AL-59412C Vehicle

Inactive ingredients used as placebo

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Theresa Landry, PhD · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2012-01-31
Completion
2012-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01312454 on ClinicalTrials.gov